SCHEMBL5196851

SCHEMBL5196851

CCCCCCCCOC(C)(C)OCCCCCCCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 9/20 0.44
CA2 P00918 9/20 0.44
CA9 Q16790 8/20 0.44
CA12 O43570 3/20 0.44
CA7 P43166 3/20 0.44
CA14 Q9ULX7 3/20 0.44
CA3 P07451 2/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44
CA5A P35218 2/20 0.44
CA5B Q9Y2D0 2/20 0.44
TSHR P16473 2/20 0.44
THRB P10828 2/20 0.44
RECQL P46063 2/20 0.43
GLA P06280 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
EPHX2 P34913 1/20 0.43
BLM P54132 1/20 0.43
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7157641 1.00 CA1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL11669727 1.00 CA1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL7918395 1.00 CA1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL7927231 1.00 CA1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL7918378 1.00 CA1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL7923990 1.00 CA1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL7918384 1.00 CA1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL9498994 0.97 CA1 (0.42) CA1CA2CA9CA12CA7
SCHEMBL13286589 0.90 THRB (0.40) CA1CA2CA9CA12CA7
SCHEMBL15256773 0.89 CA1 (0.38) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0860411-B1 Improved catalytic composition for the conversion of ethylene to alpha olefins INST FRANCAIS DU PETROLE (FR) 2003-10-29 EP claimed
US-6221986-B1 CATALYTIC OLIGOMERIZATION INSTITUT FRANCAIS DU PETROLE (FR) 2001-04-24 US claimed
US-6103654-A Catalytic composition and a process for converting ethylene to light alpha olefins INSTITUT FRANCAIS DU PETROLE (FR) 2000-08-15 US claimed
EP-0578541-B1 Process for the preparation of light alpha-olefines by oligomerisation of ethylene INST FRANCAIS DU PETROLE (FR) 1997-12-03 EP claimed
US-5496783-A CATALYSIS WITH MIXTURE OF ZIRCONIUM COMPOUND, ACETAL OR KETAL, AND ORGANOALUMINUM BROMIDE OR CHLORIDE INSTITUT FRANCAIS DU PETROLE (FR) 1996-03-05 US claimed
US-5345023-A Zirconium coordination catalysts with acetals and ketals INSTITUT FRANCAIS DU PETROLE (FR) 1994-09-06 US claimed
EP-1099983-B1 Chemically amplified positive resist composition and patterning method SHINETSU CHEMICAL CO (JP) 2014-08-06 EP disclosed
EP-1288186-B1 Preparation process of vinyl ether compounds DAICEL CHEM (JP) 2007-09-19 EP disclosed
US-7271297-B2 Process for producing vinyl ether compounds DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2007-09-18 US disclosed
EP-1826196-A2 Vinyl ether compounds Daicel Chemical Industries, Ltd. (JP) 2007-08-29 EP disclosed
US-20060205957-A1 Process for producing vinyl ether compounds ISHII YASUTAKA 2006-09-14 US disclosed
US-7074970-B2 Process for producing vinyl ether compounds DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2006-07-11 US disclosed
EP-0893442-B1 LYMPH-ABSORBABLE IMIDAZOLE DERIVATIVES SHIONOGI & CO (JP) 2005-01-12 EP disclosed
US-6221986-B1 CATALYTIC OLIGOMERIZATION INSTITUT FRANCAIS DU PETROLE (FR) 2001-04-24 US disclosed
US-6103654-A Catalytic composition and a process for converting ethylene to light alpha olefins INSTITUT FRANCAIS DU PETROLE (FR) 2000-08-15 US disclosed
US-6054591-A LYMPHOTROPIC ANTI-AIDS AGENT SHIONOGI & CO., LTD. (JP) 2000-04-25 US disclosed
EP-0893442-A1 LYMPH-ABSORBABLE IMIDAZOLE DERIVATIVES SHIONOGI & CO., LTD. (JP) 1999-01-27 EP disclosed
US-4038478-A ANTIBACTERIAL AGENTS THE UPJOHN COMPANY (US) 1977-07-26 US disclosed
US-3996205-A BACTERICIDES THE UPJOHN COMPANY (US) 1976-12-07 US disclosed
US-3984393-A BACTERICIDES THE UPJOHN COMPANY (US) 1976-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205957-A1 Process for producing vinyl ether compounds ETV6, CYP3A4, SUV39H2 CA1 2983/4885CA2 3463/4885CA9 1749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.